1. Home
  2. GHG vs INBX Comparison

GHG vs INBX Comparison

Compare GHG & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GHG

GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share

HOLD

Current Price

$1.74

Market Cap

205.1M

ML Signal

HOLD

Logo Inhibrx Inc.

INBX

Inhibrx Inc.

HOLD

Current Price

$88.40

Market Cap

430.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GHG
INBX
Founded
2004
2010
Country
China
United States
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
205.1M
430.2M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
GHG
INBX
Price
$1.74
$88.40
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
N/A
AVG Volume (30 Days)
18.8K
232.9K
Earning Date
12-30-2025
11-14-2025
Dividend Yield
5.68%
N/A
EPS Growth
N/A
N/A
EPS
0.26
N/A
Revenue
$174,012,060.00
$1,400,000.00
Revenue This Year
$19.02
$563.00
Revenue Next Year
$8.26
$230.77
P/E Ratio
$6.70
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.66
$10.81
52 Week High
$3.25
$94.47

Technical Indicators

Market Signals
Indicator
GHG
INBX
Relative Strength Index (RSI) 37.62 59.61
Support Level $1.66 $74.80
Resistance Level $1.87 $94.47
Average True Range (ATR) 0.08 6.40
MACD 0.00 -1.01
Stochastic Oscillator 34.78 64.21

Price Performance

Historical Comparison
GHG
INBX

About GHG GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share

GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The hotel network of the company comprised approximately 4,059 hotels with nearly 302,497 rooms in China, covering all centrally administrated municipalities and cities throughout all provinces and autonomous regions in China. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The company operates solely in China and generates all its revenue from China itself.

About INBX Inhibrx Inc.

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Share on Social Networks: